• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Niagen Bioscience Inc.

    4/29/25 4:19:47 PM ET
    $NAGE
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $NAGE alert in real time by email
    DEFA14A 1 defa14anage.htm DEFA14A DEFA 14A NAGE

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 14A
    Proxy Statement Pursuant to Section 14(a) of the
    Securities Exchange Act of 1934 (Amendment No.   )
    Filed by the Registrant  ☑
    Filed by a party other than the Registrant  ☐
    Check the appropriate box:
    ☐Preliminary Proxy Statement
    ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ☐Definitive Proxy Statement
    ☑Definitive Additional Materials
    ☐Soliciting Material under §240.14a-12
    NIAGEN BIOSCIENCE, INC.
    (Name of Registrant as Specified In Its Charter)
     
    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)
    Payment of Filing Fee (Check all boxes that apply):
    ☑No fee required.
    ☐Fee paid previously with preliminary materials
    ☐Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
     
    Step 1: Go to www.envisionreports.com/NAGE. Step 2: Click on Cast Your Vote or Request Materials. Step 3: Follow the instructions on the screen to log in. www.envisionreports.com/NAGE Online Go to www.envisionreports.com/NAGE or scan the QR code — login details are located in the shaded bar below. Shareholder Meeting Notice 0455WC Important Notice Regarding the Availability of Proxy Materials for the Niagen Bioscience, Inc. Annual Shareholder Meeting to be Held on June 24, 2025 Under Securities and Exchange Commission rules, you are receiving this notice that the proxy materials for the annual shareholders’ meeting are available on the Internet. Follow the instructions below to view the materials and vote online or request a copy. The items to be voted on and location of the annual meeting are on the reverse side. Your vote is important! This communication presents only an overview of the complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. The 2025 proxy statement and annual report to shareholders are available at www.Niagenbioscience.com, Investor Relations Section and: Obtaining a Copy of the Proxy Materials – If you want to receive a copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. Please make your request as instructed on the reverse side on or before June 14, 2025 to facilitate timely delivery. 2 N O T Easy Online Access — View your proxy materials and vote. When you go online, you can also help the environment by consenting to receive electronic delivery of future materials. The Sample Company Step 4: Make your selections as instructed on each screen for your delivery preferences. Step 5: Vote your shares. Votes submitted electronically must be received by 11:59 p.m., Eastern Time on June 23, 2025. MMMMMMMMMMMM M M M M M M M M M 0 0 0 0 0 1 MR A SAMPLE DESIGNATION (IF ANY) ADD 1 ADD 2 ADD 3 ADD 4 ADD 5 ADD 6 ENDORSEMENT_LINE______________ SACKPACK_____________ 1234 5678 9012 345 C 1234567890 C O Y MMMMMMM


     
    Here’s how to order a copy of the proxy materials and select delivery preferences: Current and future delivery requests can be submitted using the options below. If you request an email copy, you will receive an email with a link to the current meeting materials. PLEASE NOTE: You must use the number in the shaded bar on the reverse side when requesting a copy of the proxy materials. — Internet – Go to www.envisionreports.com/NAGE. Click Cast Your Vote or Request Materials. — Phone – Call us free of charge at 1-866-641-4276. — Email – Send an email to [email protected] with “Proxy Materials Niagen Bioscience, Inc.” in the subject line. Include your full name and address, plus the number located in the shaded bar on the reverse side, and state that you want a paper copy of the meeting materials. To facilitate timely delivery, all requests for a paper copy of proxy materials must be received by June 14, 2025. Niagen Bioscience, Inc.’s Annual Meeting of Shareholders will be held on Tuesday, June 24, 2025 at 3:00 P.M. Pacific Time. The meeting will be held at 10900 Wilshire Blvd. Suite 600, Los Angeles, CA 90024. Proposals to be voted on at the meeting are listed below along with the Board of Directors’ recommendations. The Board of Directors recommend a vote FOR all the nominees listed and FOR Proposals 2, 3, 4, and 5. 1. Election of Directors: 01 - Frank Jaksch, Jr. 02 - Robert Fried 03 - Steven Rubin 04 - Wendy Yu 05 - Gary Ng 06 - Kristin Patrick 07 - Ann Cohen 08 - Hamed Shahbazi 2. Ratification of the selection of Crowe LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025 3. Approval, on an advisory basis, of the compensation of our named executive officers, as disclosed in the accompanying proxy statement 4. Approval of amendment to the Company’s 2017 Equity Incentive Plan to increase the number of shares available for issuance by 4.75 million shares of common stock 5. Approval of the Company’s Employee Stock Purchase Plan PLEASE NOTE – YOU CANNOT VOTE BY RETURNING THIS NOTICE. To vote your shares you must go online or request a paper copy of the proxy materials to receive a proxy card. Shareholder Meeting Notice


     
     
    Get the next $NAGE alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NAGE

    DatePrice TargetRatingAnalyst
    5/27/2025$13.00Buy
    Canaccord Genuity
    More analyst ratings

    $NAGE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Niagen Bioscience, Inc. Reports Second Quarter 2025 Financial Results and Increases Full Year Outlook

    Net sales increased 37% to $31.1 million Gross margin increased 480 basis points to 65.0% Net income of $3.6 million versus breakeven in prior year period Adjusted EBITDA increased by 221% to $5.0 million Raising full year 2025 revenue outlook to 22% to 27% year-over-year growth Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced financial results for the second quarter of 2025. Second Quarter 2025 Financial Highlights Compared to Prior Year Period Total net sales increased 37% to $31.1 million, with Tru Niagen® sales reaching $22.7 million, growing 22%. Niagen® ingredient sales increased 135% to $7.4 million including food-grade and pharmaceutical-grade. Gross margin

    8/6/25 4:02:00 PM ET
    $NAGE
    Medicinal Chemicals and Botanical Products
    Health Care

    Niagen Bioscience to Present at Canaccord Genuity's 45th Annual Growth Conference

    Niagen Bioscience, Inc. (NASDAQ:NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Ozan Pamir, will participate in Canaccord Genuity's 45th Annual Growth Conference, taking place from August 12 to 14, 2024, in Boston. Mr. Fried is scheduled to participate in a fireside chat on Tuesday, August 12, at 12:00 p.m. Eastern Time (9:00 a.m. Pacific Time). To register for the Niagen Bioscience fireside chat webcast, please visit www.wsw.com. Mr. Fried and Mr. Pamir will also hold one-on-one meetings with instituti

    8/4/25 8:32:00 AM ET
    $NAGE
    Medicinal Chemicals and Botanical Products
    Health Care

    Niagen Bioscience to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025

    Niagen Bioscience, Inc. (NASDAQ:NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announces that it will hold a conference call on Wednesday, August 6, at 4:30 p.m. ET to discuss its financial results for the second quarter 2025, which ended June 30, 2025. The financial results will be reported in a press release after the close of regular stock market trading hours on Wednesday, August 6, 2025. Investor Conference Call: Niagen Bioscience management will host an investor conference call to discuss the second quarter 2025 financial results and provide a general business update on Wednesday, Aug

    7/23/25 8:34:00 AM ET
    $NAGE
    Medicinal Chemicals and Botanical Products
    Health Care

    $NAGE
    SEC Filings

    View All

    SEC Form S-8 filed by Niagen Bioscience Inc.

    S-8 - Niagen Bioscience, Inc. (0001386570) (Filer)

    8/8/25 4:05:48 PM ET
    $NAGE
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form S-8 filed by Niagen Bioscience Inc.

    S-8 - Niagen Bioscience, Inc. (0001386570) (Filer)

    8/8/25 4:05:48 PM ET
    $NAGE
    Medicinal Chemicals and Botanical Products
    Health Care

    Niagen Bioscience Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Niagen Bioscience, Inc. (0001386570) (Filer)

    8/6/25 4:06:45 PM ET
    $NAGE
    Medicinal Chemicals and Botanical Products
    Health Care

    $NAGE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on Niagen Bioscience with a new price target

    Canaccord Genuity initiated coverage of Niagen Bioscience with a rating of Buy and set a new price target of $13.00

    5/27/25 9:10:59 AM ET
    $NAGE
    Medicinal Chemicals and Botanical Products
    Health Care

    $NAGE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Shahbazi Hamed

    4 - Niagen Bioscience, Inc. (0001386570) (Issuer)

    7/3/25 10:42:17 AM ET
    $NAGE
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 4 filed by Director Yu Wing Tak Wendy

    4 - Niagen Bioscience, Inc. (0001386570) (Issuer)

    6/26/25 5:30:41 PM ET
    $NAGE
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 4 filed by Director Patrick Kristin

    4 - Niagen Bioscience, Inc. (0001386570) (Issuer)

    6/26/25 5:29:03 PM ET
    $NAGE
    Medicinal Chemicals and Botanical Products
    Health Care

    $NAGE
    Leadership Updates

    Live Leadership Updates

    View All

    Niagen Bioscience Welcomes Dr. Pinchas Cohen to Scientific Advisory Board

    Appointment of renowned gerontologist and mitochondrial biology expert underscores Niagen Bioscience's commitment to advancing cutting-edge NAD+ and healthspan research Niagen Bioscience, Inc. (NASDAQ:NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, is pleased to announce the appointment of Dr. Pinchas Cohen to its Scientific Advisory Board (SAB).​ Dr. Cohen is an internationally recognized leading expert in healthy aging and mitochondrial biology. He serves as Dean of the University of Southern California (USC) Leonard Davis School of Gerontology and is a Distinguished Professor of Gerontology

    4/29/25 8:32:00 AM ET
    $NAGE
    Medicinal Chemicals and Botanical Products
    Health Care

    $NAGE
    Financials

    Live finance-specific insights

    View All

    Niagen Bioscience, Inc. Reports Second Quarter 2025 Financial Results and Increases Full Year Outlook

    Net sales increased 37% to $31.1 million Gross margin increased 480 basis points to 65.0% Net income of $3.6 million versus breakeven in prior year period Adjusted EBITDA increased by 221% to $5.0 million Raising full year 2025 revenue outlook to 22% to 27% year-over-year growth Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced financial results for the second quarter of 2025. Second Quarter 2025 Financial Highlights Compared to Prior Year Period Total net sales increased 37% to $31.1 million, with Tru Niagen® sales reaching $22.7 million, growing 22%. Niagen® ingredient sales increased 135% to $7.4 million including food-grade and pharmaceutical-grade. Gross margin

    8/6/25 4:02:00 PM ET
    $NAGE
    Medicinal Chemicals and Botanical Products
    Health Care

    Niagen Bioscience to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025

    Niagen Bioscience, Inc. (NASDAQ:NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announces that it will hold a conference call on Wednesday, August 6, at 4:30 p.m. ET to discuss its financial results for the second quarter 2025, which ended June 30, 2025. The financial results will be reported in a press release after the close of regular stock market trading hours on Wednesday, August 6, 2025. Investor Conference Call: Niagen Bioscience management will host an investor conference call to discuss the second quarter 2025 financial results and provide a general business update on Wednesday, Aug

    7/23/25 8:34:00 AM ET
    $NAGE
    Medicinal Chemicals and Botanical Products
    Health Care

    Niagen Bioscience, Inc. Reports First Quarter 2025 Financial Results and Increases Outlook

    Total net sales of $30.5 million, up $8.3 million or 38% year-over-year, gross margin of 63.4%, net income of $5.1 million and Adjusted EBITDA of $4.9 million for the three months ended March 31, 2025 and increased full year 2025 outlook. Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced financial results for the first quarter of 2025. First Quarter 2025 Financial and Recent Operational Highlights Total net sales were $30.5 million, with $21.5 million from Tru Niagen®, up 38%, and 24%, respectively, from the prior year quarter. Total Niagen® ingredient sales, including food-grade and pharmaceutical-grade, reached $8.0 million, up 95% YoY. Delivered strong gross margin of 63.4%,

    5/7/25 4:02:00 PM ET
    $NAGE
    Medicinal Chemicals and Botanical Products
    Health Care